Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Morfini

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Circulation|February 19, 2004
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patientsA Srámek, P Bucciarelli, A B Federici, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2013
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting reportE Berntorp, B Fuchs, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 5, 2013
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA studyA Gringeri, C Leissinger, P A Cortesi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 27, 2020
Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrateG Castaman, A Borchiellini, E Santagostino, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2012
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand diseaseG Castaman, A Coppola, E Zanon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 20, 2016
Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia AR Klamroth, M Simpson, M von Depka-Prondzinski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 24, 2003
Consensus perspectives on prophylactic therapy for haemophilia: summary statementE Berntorp, J Astermark, S Björkman, et al.
Haematologica|October 1, 1979
[Thrombocythemias (author's transl)]S Tura, G Alimena, T Artusi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 19, 2014
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE surveyM Franchini, A Coppola, A Rocino, et al.
Seminars in Hematology|December 6, 2001
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombastheniaM C Poon, R d'Oiron, I Hann, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Circulation|February 19, 2004
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patientsA Srámek, P Bucciarelli, A B Federici, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 7, 2013
Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting reportE Berntorp, B Fuchs, M Makris, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 5, 2013
Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA studyA Gringeri, C Leissinger, P A Cortesi, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|July 27, 2020
Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrateG Castaman, A Borchiellini, E Santagostino, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 11, 2012
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand diseaseG Castaman, A Coppola, E Zanon, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 20, 2016
Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate(®) ) in patients with severe haemophilia AR Klamroth, M Simpson, M von Depka-Prondzinski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 24, 2003
Consensus perspectives on prophylactic therapy for haemophilia: summary statementE Berntorp, J Astermark, S Björkman, et al.
Haematologica|October 1, 1979
[Thrombocythemias (author's transl)]S Tura, G Alimena, T Artusi, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 19, 2014
Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters: the 2013 AICE surveyM Franchini, A Coppola, A Rocino, et al.
Seminars in Hematology|December 6, 2001
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombastheniaM C Poon, R d'Oiron, I Hann, et al.
Pageof 16